Search results
Ionis, Biogen Down on Ending Development of ALS Drug - Biogen (NASDAQ:BIIB), Heron Therapeutics (...
Benzinga· 4 days agoShares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
Morningstar· 5 days agoBiogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 ...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 5 days agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...
Press Releases
Morning Times· 5 days ago(Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher ...
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
InvestorPlace· 4 days agoAll on excitement for its injectable and oral treatments for weight loss, both of which are still in...
...Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast...
Benzinga· 7 days agoTOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
Top Stock Movers Now: Walmart, Canada Goose, Deere, and More
Investopedia· 5 days agoThe Dow, S&P 500, and Nasdaq rose to fresh highs intraday Thursday, with the Dow crossing the 40,000...
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March...
FOX 23 News Albany· 7 days agoBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi...
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Zacks via Yahoo Finance· 4 days agoPerformance The Nasdaq Biotechnology Index has moved up 2.32% in the past five trading sessions and ...
